BioLinq has 6 close competitors: Calyxo, Egenesis, Kriya Therapeutics.
Sector, valuation and status for each competitor.
company profile›
competitor›
competitor›
competitor›A private valuation and a public market cap share one column; each row names its basis and date.
BioLinqCalyxoEgenesisAbridge## The first fully autonomous, needle-free glucose sensor
BioLinq competes with 6 companies here: Calyxo, Egenesis, Kriya Therapeutics, Redcliffe Lifetech, Abridge, Alloy Therapeutics.
BioLinq was last valued at $400M (post-money, Apr 2025). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
The routes section explains what is realistically available for a company at this stage.
No. BioLinq is a private company; its shares do not trade on a public exchange.
The last valuation is $400M (post-money, Apr 2025).
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
